Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6157045 | American Journal of Kidney Diseases | 2016 | 9 Pages |
Abstract
A substantial proportion of patients discontinue HHD therapy within the first 12 months of use of the modality. Patients with diabetes, substance use, nonlisting for kidney transplantation, and urban residence are at greater risk for discontinuation. Targeting high-risk patients for increased support from clinical teams is a potential strategy for reducing HHD therapy discontinuation and increasing technique survival.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Rebecca Kurnik MD, Nandita PhD, C. Michael MD, Jiaqi MS, Christopher BA, Dan MD, Joel D. MD, Laura M. MD,